Sarepta Therapeutics (SRPT) Falls on New Short Report
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Biotech darling Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is under heavy pressure Wednesday (-9.4%) in part on a new short report from Favus. The report claims that the clinical trial data for eteplirsen is not enough for early/accelerated FDA approval, and eteplirsen likely does not work at all.
On twitter, TheStreet's biotech master Adam Feuerstein (@adamfeuerstein) said the report "is just a rehash of old short arguments."
A screen-grab of the first page of the report can be seen here.
On twitter, TheStreet's biotech master Adam Feuerstein (@adamfeuerstein) said the report "is just a rehash of old short arguments."
A screen-grab of the first page of the report can be seen here.
Here's a screen grab of Favus' $SRPT short report. First page --> pic.twitter.com/0ksTkIB9Ep
— Adam Feuerstein (@adamfeuerstein) October 9, 2013
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple (AAPL) announces 'Let Loose,' a special online event to be held in May
- Visa (V) earnings and revenue exceed estimates in Q2, shares rise
- Tesla (TSLA) soars on Q1 print
Create E-mail Alert Related Categories
Momentum Movers, Short Sales, Trader TalkRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!